Allogene Therapeutics Appoints Industry Leaders Elizabeth (Liz) Barrett and Vicki Sato, Ph.D., to its Board of Directors
August 02 2021 - 8:30AM
Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage
biotechnology company pioneering the development of allogeneic CAR
T (AlloCAR T™) therapies for cancer, today announced the
appointment of Elizabeth (Liz) Barrett and Vicki Sato, Ph.D. to
the company’s Board of Directors. Ms. Barrett, an executive
with deep experience in the commercialization of novel oncology
therapies, is currently the President and Chief Executive Officer
(CEO) of UroGen Pharma (Nasdaq: URGN). Dr. Sato, former faculty
member at Harvard University and Harvard Business School, has
an exceptional track record of execution as an executive at several
leading biotechnology companies.
“We are very fortunate to welcome Liz and Vicki to our Board of
Directors,” said David Chang, M.D., Ph.D., President, CEO and
Co-Founder of Allogene Therapeutics. “These talented executives
will provide critical guidance as we plan to initiate our first
pivotal study later this year and position Allogene to potentially
become the first company to commercialize an allogeneic CAR T
therapy. Liz is a CAR T veteran whose deep knowledge of the
oncology marketplace will be invaluable as Allogene seeks to
commercialize off-the-shelf therapies for cancer patients. Vicki is
a skillful and strategic thinker whose scientific and business
acumen will help steer us as we enter the next phase of growth in
the field of allogeneic cell therapy.”
Ms. Barrett is currently the President and CEO of UroGen Pharma,
a biotechnology company that develops and commercializes treatments
for urologic and uro-oncological conditions. At UroGen, Liz
spearheaded the 2020 approval of Jelmyto® for the treatment of
low-grade upper tract urothelial carcinoma. She previously served
as CEO of Novartis Oncology, where she managed the development and
launch of the autologous CAR T therapy Kymriah® (tisagenlecleucel).
Prior to her tenure at Novartis, she held several leadership
positions at Pfizer, including Global President and General Manager
of Oncology, and led the rollout of Ibrance®. She has also held
leadership roles at Cephalon and Johnson & Johnson. Ms. Barrett
currently serves on the Board of Directors of Sage
Therapeutics.
“I am excited to join Allogene’s Board of Directors and resume
participation in one of the most promising therapeutic modalities
within oncology,” said Ms. Barrett. “I believe allogeneic cell
therapy is the future of CAR T, and I am eager to play a role in
bringing this potentially revolutionary therapy to many more
patients with hematologic and solid tumor malignancies.”
Dr. Sato served as President of Vertex Pharmaceuticals where she
was responsible for research and development, business and
corporate management, and commercial, legal and financial
operations. Before joining Vertex, Dr. Sato was Vice President of
Research at Biogen, Inc., where she led programs in inflammation,
thrombosis, and HIV and contributed to the executive management of
the company. She also served as a member of the Biogen Scientific
Advisory Board. Dr. Sato began her career as a Professor in the
Department of Cell and Developmental Biology at Harvard University
and then returned to academia from 2006-2017 to serve as a
Professor of the Practice in Molecular and Cell Biology at Harvard
University and a Professor of Management Practice at Harvard
Business School. Dr. Sato is currently on the Board of Directors at
Denali Therapeutics, Vir Biotechnology and Akouos.
“I am honored to join Allogene’s Board of Directors,” said Dr.
Sato. “Allogene has produced exciting clinical data showcasing the
potential for allogeneic CAR T therapy to offer distinct advantages
over autologous cell therapy. I believe it is still early days in
terms of our ability to unlock the full potential of cell therapy
and look forward to supporting Allogene’s leadership position in
this field.”
About Allogene TherapeuticsAllogene
Therapeutics, with headquarters in South San Francisco, is a
clinical-stage biotechnology company pioneering the development of
allogeneic chimeric antigen receptor T cell (AlloCAR T™) therapies
for cancer. Led by a management team with significant experience in
cell therapy, Allogene is developing a pipeline of “off-the-shelf”
CAR T cell therapy candidates with the goal of delivering readily
available cell therapy on-demand, more reliably, and at greater
scale to more patients. For more information, please visit
www.allogene.com, and follow @AllogeneTx on Twitter and
LinkedIn.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements for purposes of the safe harbor provisions of the
Private Securities Litigation Reform Act of 1995. The press release
may, in some cases, use terms such as "predicts," "believes,"
"potential," "proposed," "continue," "estimates," "anticipates,"
"expects," "plans," "intends," "may," "could," "might," "will,"
"should" or other words that convey uncertainty of future events or
outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding intentions,
beliefs, projections, outlook, analyses or current expectations
concerning, among other things: timing and ability to advance to a
pivotal trial of an AlloCAR T™ therapy; ability to generate
positive data, obtain regulatory approval and commercialize any
AlloCAR T™ therapy; and the potential benefits of AlloCAR T™
therapy. Various factors may cause differences between Allogene’s
expectations and actual results as discussed in greater detail in
Allogene’s filings with the SEC, including without limitation in
its Form 10-Q for the quarter ended March 31, 2021. Any
forward-looking statements that are made in this press release
speak only as of the date of this press release. Allogene assumes
no obligation to update the forward-looking statements whether as a
result of new information, future events or otherwise, after the
date of this press release.
AlloCAR T™ is a trademark of Allogene Therapeutics,
Inc.
Allogene Media/Investor Contact:Christine
CassianoChief Communications Officer(714)
552-0326Christine.Cassiano@allogene.com
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Mar 2024 to Apr 2024
Allogene Therapeutics (NASDAQ:ALLO)
Historical Stock Chart
From Apr 2023 to Apr 2024